01—Abstract
Summary
Summary of the 10-K filed February 16, 2011. Cited figures are marked; the original filing is the authoritative source.
Quest Diagnostics, a leader in diagnostic testing, reported $7.4 billiona in net revenues for the fiscal year ended December 31, 2010.
The company's strategy focuses on leveraging its extensive assets, driving medical innovation, delivering a superior patient experience, and maintaining high quality through Six Sigma processes. Significant investments in healthcare information technology, such as the Care360 suite, are aimed at improving patient care and clinician workflow, with the Care360 EHR solution receiving ONC-ATCB certification. The company operates in a competitive market influenced by healthcare reform, demographic trends, and technological advancements.
Quest Diagnostics' diverse revenue streams include clinical testing (91%b of 2010 revenues), life insurer services, clinical trials testing, diagnostic products, and employer services. Despite a slight decrease in net revenues compared to 2009, the company managed its costs effectively, resulting in stable operating income as a percentage of revenue, supported by reduced bad debt expenses and operational efficiencies.
02—Key points
Key Highlights
- Quest Diagnostics generated $7.4 billion in net revenues for the fiscal year ended December 31, 2010.
- The company's strategy emphasizes leveraging its broad assets, medical innovation, superior patient experience, and Six Sigma quality.
- Clinical testing accounted for the vast majority of revenue (91%), with other segments including life insurer services, clinical trials, and diagnostics products.
- Investments in healthcare IT, notably the Care360 suite, are highlighted as a differentiator, supporting electronic health records and physician workflow.
- The company experienced a slight revenue decline of 1.2% compared to the prior year, primarily due to lower clinical testing volumes.
- Operating income remained strong as a percentage of revenue, supported by cost management initiatives, including reduced bad debt expenses.
- Quest Diagnostics continues to operate in a dynamic healthcare landscape influenced by regulatory changes, competition, and technological advancements.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2010, Quest Diagnostics Inc kept $0.10.
- Revenue$7.26B100.0%
- Cost of revenue−$4.21B58.0%
- Gross profit$3.05B42.0%
- Operating costs−$1.77B24.4%
- Operating income$1.28B17.7%
- Interest, other & tax−$562.7M7.8%
- Net income$720.9M9.9%
Where FY2010 revenue went
$7.26B- Cost of revenue: $4.28B, 59% of revenue
- SG&A: $1.66B, 23% of revenue
- Net income: $720.9M, 9.9% of revenue
- Other operating costs: $42.2M, 0.6% of revenue
- Interest, other & tax: $562.7M, 7.8% of revenue
Kept 9.9% as net incomeOther operating costs $42.2M · 0.6%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2010filed February 16, 2011Financial Statements
FY2010 against FY2009
| Line item | FY2010FY2009 | Change |
|---|---|---|
| Revenue | $7.26B$7.46B | −2.6% |
| Cost of Revenue | $4.28B$4.32B | −1.1% |
| Gross Profit | $3.05B$3.13B | −2.6% |
| SG&A Expenses | $1.66B$1.75B | −5.1% |
| Operating Expenses | $5.98B$6.10B | −2.0% |
| Operating Income | $1.28B$1.36B | −5.6% |
| Interest Expense | $147.50M$146.59M | +0.6% |
| Net Income | $720.89M$729.11M | −1.1% |
| EPS (Basic) | $4.08$3.91 | +4.3% |
| EPS (Diluted) | $4.05$3.87 | +4.7% |
| Shares Outstanding (Basic) | 175.68M185.95M | −5.5% |
| Shares Outstanding (Diluted) | 177.32M187.80M | −5.6% |
05—Questions
Frequently Asked Questions
What were Quest Diagnostics' main revenue drivers in 2010?
In 2010, Quest Diagnostics derived the vast majority of its revenue (91%) from its clinical testing business. Other significant revenue streams included life insurer services, clinical trials testing, healthcare information technology, and diagnostic products.
How did the company address healthcare reform and its impact on operations?
Quest Diagnostics acknowledged the significant impact of U.S. healthcare reform legislation. While expecting expanded coverage to benefit industry utilization, the company noted potential offsets from cost-reduction provisions impacting Medicare fee schedules. They expressed confidence in their ability to adapt to these evolving market forces.
What is Quest Diagnostics' strategy for growth and competitive advantage?
Quest Diagnostics' strategy is multifaceted, focusing on leveraging its extensive network and capabilities, leading in medical innovation and IT solutions, delivering a superior patient experience, and continuously driving quality through Six Sigma processes. The company also aims to expand its geographic reach and its portfolio in point-of-care testing.
Were there any significant legal or regulatory issues mentioned in the filing?
The filing mentions ongoing legal proceedings, including investigations related to billing practices with MediCal (California Medicaid) and a federal False Claims Act complaint. While the company believes it is in compliance, it has engaged in discussions and settled some matters, indicating a continued focus on compliance and risk management.
06—Continue